These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26750740)

  • 1. Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.
    Saillard C; El Cheikh J; Granata A; Coso D; Schiano JM; Bouabdallah R; Blaise D; Charrier N; Broussais F
    Leuk Lymphoma; 2016; 57(3):714-6. PubMed ID: 26750740
    [No Abstract]   [Full Text] [Related]  

  • 2. Graft-versus-lymphoma effect plus vorinostat as successful approach in a case of refractory gastric peripheral T cell lymphoma, not otherwise specified, after reduced intensity conditioning allogeneic hematopoietic cell transplant.
    Devarakonda SS; Shahan JL; Takalkar A; Chaudhery SI; Jean G; Koshy NV; Hildebrandt GC
    Leuk Lymphoma; 2013 Nov; 54(11):2545-7. PubMed ID: 23442066
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduced intensity conditioning allogeneic hematopoietic stem cell transplant could be beneficial to angioimmunoblastic T-cell lymphoma patients with hemophagocytic lymphohistiocytosis.
    Yu JT; Hwang WL; Wang RC; Teng CL
    Ann Hematol; 2012 May; 91(5):805-807. PubMed ID: 21894473
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
    Ribrag V; Kim WS; Bouabdallah R; Lim ST; Coiffier B; Illes A; Lemieux B; Dyer MJS; Offner F; Felloussi Z; Kloos I; Luan Y; Vezan R; Graef T; Morschhauser F
    Haematologica; 2017 May; 102(5):903-909. PubMed ID: 28126962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literature.
    Jethwa KD; Bishton MJ; Fox CP
    Br J Haematol; 2017 Aug; 178(3):476-479. PubMed ID: 27146257
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose therapy and stem cell transplantation.
    Zinzani PL
    Semin Hematol; 2010 Apr; 47 Suppl 1():S15-7. PubMed ID: 20359581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
    Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
    Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term successful use of belinostat in a patient with relapsed-refractory angioimmunoblastic lymphoma who has previously been heavily treated.
    Atalay F; Yeşilaltay A
    J Cancer Res Ther; 2024 Apr; 20(3):1049-1052. PubMed ID: 39023617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.
    Lopez G; Liu J; Ren W; Wei W; Wang S; Lahat G; Zhu QS; Bornmann WG; McConkey DJ; Pollock RE; Lev DC
    Clin Cancer Res; 2009 May; 15(10):3472-83. PubMed ID: 19417021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
    Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.
    von Tresckow B; Morschhauser F; Szer J; Eichenauer DA; Abramson JS; Sureda A; Engert A
    Leuk Lymphoma; 2017 Jan; 58(1):222-225. PubMed ID: 27184350
    [No Abstract]   [Full Text] [Related]  

  • 12. Current and novel treatment options for peripheral T-cell lymphoma.
    Horwitz SM
    Clin Adv Hematol Oncol; 2015 Jul; 13(7):463-6. PubMed ID: 26353042
    [No Abstract]   [Full Text] [Related]  

  • 13. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
    Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
    Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
    Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
    Dickinson M; Ritchie D; DeAngelo DJ; Spencer A; Ottmann OG; Fischer T; Bhalla KN; Liu A; Parker K; Scott JW; Bishton M; Prince HM
    Br J Haematol; 2009 Oct; 147(1):97-101. PubMed ID: 19663825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
    Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
    Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
    Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
    Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.